Nebius Accelerates Next Generation of Healthcare and Life Sciences Innovation with Inaugural AI Discovery Awards

Rhea-AI Summary

Nebius (NASDAQ: NBIS) has announced the winners of its first AI Discovery Awards, providing over $850,000 in GPU cloud and inferencing credits to innovative healthcare and life sciences companies. The competition selected four main winners from 257 global applications, each receiving $100,000 in GPU credits. Winners include Ataraxis AI (cancer treatment prediction with 30% higher accuracy), Aikium (targeting undruggable proteins), Transcripta Bio (transcriptomic atlas with billion gene responses), and MetaSight Diagnostics (population-scale disease diagnostics). Second and third-place winners received $50,000 and $30,000 respectively, while seven honorable mentions in each category got $5,000 in credits. The awards were judged by 19 experts from leading organizations including AstraZeneca BioPharma, NVIDIA, Monte Rosa Therapeutics, and Utrecht University.

Positive

• Significant financial support with over $850,000 in GPU credits to advance healthcare AI innovation
• Strong validation process with 19 independent judges from leading organizations
• Winners demonstrated concrete results: Ataraxis AI achieved 30% higher accuracy in cancer prediction
• Large-scale participation with 257 global applications showing program's reach

Negative

• None.

• Full-stack AI infrastructure provider backs pioneering companies in biotech, drug discovery, genomics and multiomics, and healthcare diagnostics with GPU cloud and inferencing credits totalling over $850,000.

Amsterdam, Netherlands--(Newsfile Corp. - June 23, 2025) - Nebius (NASDAQ: NBIS) has named the winners of its inaugural AI Discovery Awards, awarding top prizes of $100,000 in GPU credits each to four companies pioneering AI breakthroughs in cancer prediction, protein targeting, transcriptomic mapping, and precision diagnostics.

The winners, selected from 257 global applications by a panel of 19 independent judges from leading biotech, pharma, research and venture capital organizations, represent validated AI solutions with clear paths to market impact:

Biotechnology: Ataraxis AI - Cancer treatment prediction platform achieved 30% higher accuracy than standard genomic tests in clinical validation across 7,500 patients from 15 institutions. The Kestrel foundation model, trained on hundreds of millions of pathology images, helps oncologists determine whether aggressive treatments like chemotherapy are necessary.

Drug Discovery: Aikium - Targets "undruggable" proteins comprising half the human proteome using its Yotta-ML² platform. The company has secured partnerships with four organizations, including three top cancer hospitals, based on successful GPCR proof-of-concept work.

Genomics and Multiomics: Transcripta Bio - Built a high-resolution transcriptomic atlas containing over a billion gene responses to power AI models predicting biological responses from drug molecules. Recently partnered with Microsoft Research to identify new disease-gene associations.

HealthTech: MetaSight Diagnostics - Pioneers population-scale disease diagnostics through advanced blood testing, creating the world's largest blood molecular database from over 500,000 participants in the Israel Multi-OMICS Screening Trial. Developing screening products for colorectal cancer and metabolic diseases.

"These teams are pushing the frontier of AI in healthcare and life sciences with credible science and clear paths to market," said Arkady Volozh, founder and CEO of Nebius. "We're proud to help them turn research into real-world impact."

Held for the first time this year, the Nebius AI Discovery Awards connect promising companies leveraging AI in healthcare and life sciences with the computational infrastructure and expertise needed to scale their innovations.

Category winners receive $100,000 in GPU credits for Nebius AI Cloud, with second- and third-placed companies receiving $50,000 and $30,000, respectively, as well as other benefits including mentorship and networking support.

A further seven "honorable mentions" in each category received $5,000 in GPU cloud credits. All participants in the AI Discovery Awards were also granted inferencing credits for Nebius AI Studio.

"These companies represent meaningful progress in applying AI to healthcare's most challenging problems," said Dr. Ilya Burkov, Global Head of Healthcare & Life Sciences Growth at Nebius. "From targeting previously undruggable proteins to predicting cancer treatment outcomes with unprecedented accuracy, these teams are building tools that will directly impact patient care and health outcomes."

2025 Nebius AI Discovery Awards winners

	Biotechnology	Drug Discovery	Genomics & Multiomics	HealthTech
1st	Ataraxis AI	Aikium	Transcripta Bio	MetaSight Diagnostics
2nd	Feel Therapeutics	Serna Bio	Converge Bio	Slingshot AI
3rd	Nostics	Leash Bio	Infinnimune	iSono Health

The AI Discovery Awards were evaluated by 19 independent judges from leading pharmaceutical, biotechnology, research and healthcare organizations including AstraZeneca BioPharma, NVIDIA, Monte Rosa Therapeutics and Utrecht University.

More information about the Nebius AI Discovery Awards - including all shortlisted companies in each category, qualification criteria and a full jury list - can be found on Nebius's website at https://nebius.com/ai-discovery-award

About Nebius

Nebius is a technology company building full-stack infrastructure to service the explosive growth of the global AI industry, including large-scale GPU clusters, an AI-native cloud platform, and tools and services for developers. Headquartered in Amsterdam and listed on Nasdaq, the Company has a global footprint with R&D hubs across Europe, North America and Israel.

Nebius's AI Cloud has been built from the ground up for intensive AI workloads. With proprietary software and hardware designed in-house, Nebius gives AI builders the compute, storage, managed services and tools they need to build, tune and run their models.

To learn more please visit www.nebius.com

Contact

media@nebius.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256456

FAQ

What is the Nebius AI Discovery Awards program and how much funding does it provide?

The Nebius AI Discovery Awards is an inaugural program providing over $850,000 in GPU cloud and inferencing credits to companies innovating in healthcare and life sciences, with top winners receiving $100,000 each in GPU credits.

Who are the main winners of the 2025 Nebius AI Discovery Awards?

The main winners are Ataraxis AI (Biotechnology), Aikium (Drug Discovery), Transcripta Bio (Genomics & Multiomics), and MetaSight Diagnostics (HealthTech), each receiving $100,000 in GPU credits.

What breakthrough did Ataraxis AI achieve in cancer treatment prediction?

Ataraxis AI's platform achieved 30% higher accuracy than standard genomic tests in clinical validation across 7,500 patients from 15 institutions using their Kestrel foundation model.

How many applications did NBIS receive for the AI Discovery Awards?

Nebius received 257 global applications for the AI Discovery Awards, which were evaluated by 19 independent judges from leading pharmaceutical, biotechnology, research and healthcare organizations.

What is the selection process for the Nebius AI Discovery Awards?

Applications were evaluated by 19 independent judges from organizations like AstraZeneca BioPharma, NVIDIA, Monte Rosa Therapeutics, and Utrecht University, focusing on validated AI solutions with clear paths to market impact.